CN102675403A

CN102675403A - Synthesis of anti-hepatitis B medicine LQC-X and application thereof

Info

Publication number: CN102675403A
Application number: CN2011100551015A
Authority: CN
Inventors: 雷海民; 任健; 王鹏龙; 蔡程科; 李强; 程云
Original assignee: 雷海民
Current assignee: Beijing Measuring Technology Development Co Ltd
Priority date: 2011-03-09
Filing date: 2011-03-09
Publication date: 2012-09-19
Anticipated expiration: 2031-03-09
Also published as: CN102675403B

Abstract

The invention relates to the field of chemical and biological sciences, in particular to LQC-X structural formula I, and synthesis and application of intermediate of LQC-X, wherein a maximum dosage of LQC-X6 given to an mouse is 2000 mg/kg once in one day; the mouse is continuously observed for 7 days; no toxic reaction appears, and the medicine is proven to have quite high safety; and it is proved through pharmacodynamics experiments that LQC-X compounds have obvious anti-hepatitis B virus action and liver protecting and transaminase lowering action. The compounds can be used for preparing medicines for preventing and treating diseases of hepatitis B, chronic liver cirrhosis and the like. The structural formula I of LQC-X is shown in the description.

Description

Synthetic and the application of anti-hbv drug LQC-X

Technical field

The present invention relates to chemistry and bio-science field; Be specifically related to the synthetic and application of LQC-X general structure I and midbody thereof; Wherein the maximum dosage 2000mg/kg of LQC-X6 mouse odd-numbered day single observed 7 days continuously, toxic reaction do not occur; Show that this drug safety is very high, this compounds of pharmacodynamic experiment proof has tangible anti-HBV effect and function for protecting liver and reducing enzyme activity.Can be used for preparing the medicine of prevention and diseases such as treatment hepatitis B, chronic liver cirrhosis.

LQC-X general structure I

Background technology

B virus (Hepatitis B virus, HBV) hepatitis and liver cirrhosis, the liver cancer of being brought out thus are to threaten one of healthy major disease of human life, and the efficacious therapy means are not arranged at present as yet; Except that vaccine, Interferon, rabbit, lamivudine etc. is widely used in clinical, because spinoff is big; Expensive, the virus knock-on waits and has received great restriction, therefore; Seek anti-hepatic-B virus medicine, be the key subjects that numerous biologists, chemist face always.

Oleanolic Acid has many-sided pharmacological actions such as anti-inflammatory, antitumor and lipidemia; In plurality of Chinese and compound all as index property composition, at present as commonly used protect the liver the OTC medicine be used to treat acute chemical damage, chronic liver cirrhosis and hepatic fibrosis [Xi Jia is etc. pharmacokinetic studies progress [J] in Oleanolic Acid oral prepns and the body thereof. Chinese Journal of New Drugs; 2009; (06): 507-510], with this compound be active guide carry out structural modification many with antitumor be screening index [Zheng Kaibo is etc. the progress of Oleanolic Acid structural modification and anti-tumor activity [J]. the national college of education in the south of Guizhou Province journal; 2009, (06): 11-14].

The present invention utilizes inside and outside hepatitis B virus resisting model, from multiple Oleanolic Acid structural modification thing, filters out one type of compound that anti-HBV effect is comparatively clear and definite, and called after LQC-X.

Summary of the invention

One of the object of the invention provides the general structure (formula 1) of LQC-X.

Two of the object of the invention provides the synthesis route of LQC-X general structure I and midbody thereof.

Three of the object of the invention provides the application at aspects such as hepatitis B virus resisting, protecting liver, lowering enzymes of LQC-X and midbody thereof.

Formula 1LQC-X general structure I

The object of the invention can be realized through following measures:

The method of a kind of synthetic LQC-X comprises the following steps:

(1) Oleanolic Acid (compound 1) is dissolved in organic solvent, with brominated reagent reacting generating compound LQC-X1 takes place under the catalysis of catalyzer to eliminate under the certain temperature;

(2) the compound L QC-X1 with above-mentioned generation is dissolved in organic solvent, with Eosiy free radical reaction takes place under the certain temperature and generates compound L QC-X2;

(3) the compound L QC-X1 with above-mentioned generation is dissolved in organic solvent, with Eosiy free radical reaction takes place under the certain temperature and generates compound L QC-X3;

(4) the compound L QC-X2 with above-mentioned generation is dissolved in organic solvent, under the certain temperature, generates compound L QC-X4 with oxygenant generation oxidizing reaction;

(5) the compound L QC-X3 with above-mentioned generation is dissolved in organic solvent, under the certain temperature, generates compound L QC-X5 with oxygenant generation oxidizing reaction;

(6) the compound L QC-X1 with above-mentioned generation is dissolved in organic solvent, under the certain temperature, generates compound L QC-X6 with oxygenant generation oxidizing reaction;

(7) Oleanolic Acid (compound 1) is dissolved in organic solvent, under the certain temperature, generates compound L QC-X7 with oxygenant generation oxidizing reaction;

(8) Oleanolic Acid (compound 1) is dissolved in organic solvent, under the certain temperature, reacting with the bromo Ligustrazine generates compound L QC-X8;

(9) the compound L QC-X1 with above-mentioned generation is dissolved in organic solvent, and under the certain temperature, reacting with the bromo Ligustrazine generates compound L QC-X9;

(10) the compound L QC-X6 with above-mentioned generation is dissolved in organic solvent, and under the certain temperature, reacting with the bromo Ligustrazine generates LQC-X10;

The reaction formula of step in the aforesaid method (1), (2), (3), (4), (5), (6), (7), (8), (9), (10) is:

The method of said synthetic LQC-X, the organic solvent that wherein uses in the step (1) are the perhaps mixtures of their various ratios of the ether that contains 2-20 carbon atom, alcohol, alkane, aromatic hydrocarbon, ketone, haloalkane, acid amides, nitrile, ester; Brominated reagent is bromo-succinimide (NBS), hydrogen bromide, acetyl bromide; Temperature is-20 ℃ to 250 ℃; Catalyzer is that organic bases is representative with pyridine and triethylamine, or wavelength is the 290-800nm light source; The mol ratio of compound L QC-X1 and brominated reagent is 1: 1-20;

The method of said synthetic LQC-X, the organic solvent that wherein uses in the step (2), step (3) are the perhaps mixtures of their various ratios of the aromatic hydrocarbon that contains 1-20 carbon atom, alkane, ether, ketone, haloalkane, acid amides, nitrile, ester; Temperature is-10 ℃ to 150 ℃; Free radical reaction reagent is Eosiy; Catalyzer is that wavelength is the 290-800nm light source; The mol ratio of compound L QC-X2, LQC-X3 and radical reagent is respectively 1: 1-10;

The method of said synthetic LQC-X, the organic solvent that wherein uses in step (4)-(7) are the perhaps mixtures of their various ratios of the aromatic hydrocarbon that contains 1-20 carbon atom, alkane, ether, ketone, haloalkane, acid amides, nitrile, ester; Temperature is-20 ℃ to 150 ℃; Oxygenant is representative with sulfuric acid, chromic acid and Jones reagent; The mol ratio of compound L QC-X4, LQC-X5, LQC-X6 and LQC-X7 and oxygenant is respectively 1: 1-10;

The method of said synthetic LQC-X, the organic solvent that wherein uses in step (8)-(10) are the perhaps mixtures of their various ratios of the ether that contains 2-20 carbon atom, alcohol, alkane, aromatic hydrocarbon, ketone, haloalkane, acid amides, nitrile, ester; Temperature is-20 ℃ to 250 ℃; Catalyzer is various bases, and mineral alkali is representative with salt of wormwood; The mol ratio of compound L QC-X8, LQC-X9, LQC-X10 and catalyzer is respectively 1: 1-20;

(11) said synthetic LQC-X, external have obvious restraining effect to the virus antigen in the HepG2.2.15 emiocytosis supernatant;

(12) said synthetic LQC-X, external have obvious restraining effect to HepG2.2.15 cell virus HBV-DNA;

(13) said synthetic LQC-X6 can effectively suppress duplicating of dhbv dna in the duckling body;

(14) said synthetic LQC-X6, on the chmice acute liver injury of protecting tetracol phenixin to cause, rat chronic fibrosis effect, curative effect is obvious, can delay the degree of injury of liver;

(15) the lower toxicity of performance in the said synthetic LQC-X6, body, injected in mice LD ₅₀Be 785.05mg/kg, mouse stomach single maximum tolerated dose is 2000mg/kg;

(16) said synthetic LQC-X can be made into multiple formulations such as oral dosage form, injection type and exterior-applied formulation, is applied to the prevention and the treatment aspect of hepatitis B.

Embodiment

Below be the embodiment of The compounds of this invention, but these embodiment and do not mean that limitation of the present invention.

Preparation embodiment 1LQC-X1's is synthetic

With Oleanolic Acid 9.12g (0.02mol), 400ml tetracol phenixin, 4.27gN-bromo-succinimide (about 0.024mol) place 500ml reaction flask, illumination, magnetic agitation to be heated to 74 ℃ and refluxed 4 hours, and reaction is not to there being raw material, and reaction finishes.Reclaim reaction solution to doing, with the solid after reclaiming with 200ml ETHYLE ACETATE thermosol, filtered while hot, 24 hours crystallizatioies of room temperature placement obtain a large amount of coarse-grains, re-crystallizing in ethyl acetate once obtains LQC-X1, white plates crystallization 7.13g, reaction yield is 78.5%.m.p.276.7-278.4℃。

The LQC-X1 spectrum data of being correlated with:

ESI-MS：[M-1] ^-453

¹H-NMR (500MHZ, CDCl ₃): 083,0.93,0.97,1.00,1.05,1.06,1.20 (3H, each, s, 7 * CH ₃) 2.99 (m, 1H, 3-OH), 3.28 (m, 1H, H-3), 5.58 (d, 1H, J=5.5HZ, H-12), 5.62 (d, 1H, J=5.5HZ, H-11) .1.000～2.500 (24H, methylene radical in the three obedient mother nucleus structures and methyne hydrogen signals);

¹³C-NMR(500MHZ，CDCl ₃)：38.9(C-1)，37.1(C-2)，78.7(C-3)，38.9(C-4)，51.2(C-5)，18.2(C-6)，33.8(C-7)，40.7(C-8)，154.7(C-9)，42.4(C-10)，120.7(C-11)，115.6(C-12)，144.9(C-13)，45.9(C-14)，27.9(C-15)，23.6(C-16)，45.9(C-17)，39.4(C-18)，25.1(C-19)，30.7(C-20)，32.2(C-21)，32.2(C-22)，28.3(C-23)，15.7(C-24)，20.2(C-25)，20.4(C-26)，27.0(C-27)，183.5(C-28)，32.9(C-29)，23.6(C-30).

Preparation embodiment 2LQC-X2's is synthetic

Take by weighing the about 4.54g of LQC-X1 (0.01mol), be dissolved in the 500ml methylene dichloride, add Eosiy (alcohol dissolves) 200mg, ventilation, illumination reaction 10h.After reaction finished, with 3 times of amount saturated sodium bicarbonate solution washed twice, washing was to neutral, and SODIUM SULPHATE ANHYDROUS 99PCT dewaters, and reclaims methylene dichloride, crosses silicagel column, sherwood oil: ETHYLE ACETATE=5: 1 wash-outs.Get LQC-X2, be total to 2.05g, reaction yield 42.0%.

The LQC-X2 spectrum data of being correlated with:

ESI-MS[M-1] ^-487

¹H-NMR (500MHZ, CDCl ₃): 0.86,0.98,0.99,1.02,1.08,1.28,1.27 (3H, each, s, 7 * CH ₃), 3.01 (1H, m, H-3), 3.25 (1H, m, 3-OH), 6.02 (1H, s, H-12), 1.000～2.500 (24H, methylene radical in the three obedient mother nucleus structures and methyne hydrogen signals);

¹³C-NMR(500MHZ，CDCl ₃)：36.7(C-1)，27.2(C-2)，77.9(C-3)，40.5(C-4)，50.3(C-5)，17.3(C-6)，34.0(C-7)，39.4(C-8)，87.8(C-9)，36.4(C-10)，192.4(C-11)，121.6(C-12)，178.7(C-13)，41.8(C-14)，27.5(C-15)，20.2(C-16)，46.0(C-17)，44.0(C-18)，43.6(C-19)，29.7(C-20)，31.6(C-21)，34.1(C-22)，28.1(C-23)，16.0(C-24)，14.2(C-25)，23.2(C-26)，24.4(C-27)，184.0(C-28)，33.2(C-29)，23.8(C-30).

Preparation embodiment 3LQC-X3's is synthetic

Take by weighing the about 4.54g of LQC-X1 (0.01mol), be dissolved in the 500ml methylene dichloride, add Eosiy (alcohol dissolves) 200mg, ventilation, illumination reaction 10h.After reaction finished, with 3 times of amount saturated sodium bicarbonate solution washed twice, washing was to neutral, and SODIUM SULPHATE ANHYDROUS 99PCT dewaters, and reclaims methylene dichloride, crosses silicagel column, sherwood oil: ETHYLE ACETATE=5: 1 wash-outs.The LQC-X3 reaction yield is about 10%.

The LQC-X3 spectrum data of being correlated with:

¹H-NMR (500MHZ, CDCl ₃): 0.83,0.96,0.99,1.03,1.05,1.20,1.21 (3H, each, s, 7 * CH ₃), 3.22 (1H, m, H-3), 4.33 (1H, d, J=2.5HZ, H-11), 5.38 (1H, d, J=2.5HZ, H-12), 1.000～2.500 (24H, methylene radical in the three obedient mother nucleus structures and methyne hydrogen signals);

¹³C-NMR(500MHZ，CDCl ₃)：37.0(C-1)，27.2(C-2)，78.4(C-3)，39.3(C-4)，50.8(C-5)，17.6(C-6)，34.2(C-7)，37.7(C-8)，78.9(C-9)，37.2(C-10)，65.7(C-11)，118.0(C-12)，119.2(C-13)，44.0(C-14)，27.7(C-15)，20.7(C-16)，47.7(C-17)，51.4(C-18)，43.5(C-19)，29.7(C-20)，32.9(C-21)，34.2(C-22)，28.1(C-23)，15.5(C-24)，15.4(C-25)，25.0(C-26)，24.6(C-27)，179.4(C-28)，33.3(C-29)，24.0(C-30).

Preparation embodiment 4LQC-X4's is synthetic

Take by weighing the about 500mg of LQC-X2, the 50ml acetone solution slowly drips the chromic acid solution (1.6mmol) of 4ml preparation under ice-water bath in the 100ml reaction flask, drip off in the 5min.Reaction is not to there being raw material, and reaction finishes.Reaction solution is poured in the mixture of ice and water of 600ml, stirred, placement is spent the night, suction filtration.Filter cake is used the ethanol periodic crystallisation, promptly gets LQC-X4.Reaction yield is 90%.

The LQC-X4 spectrum data of being correlated with:

¹H-NMR (600MHZ, CDCl ₃): 0.95,0.95,1.00,1.10,1.13,1.37,1.49 (3H, each, s, 7 * CH ₃), 6.02 (1H, s, H-12), 1.000～2.500 (24H, methylene radical in the three obedient mother nucleus structures and methyne hydrogen signals);

¹³C-NMR(600MHZ，CDCl ₃)：36.7(C-1)，33.1(C-2)，215.4(C-3)，37.0(C-4)，50.8(C-5)，18.3(C-6)，34.0(C-7)，39.8(C-8)，87.8(C-9)，47.6(C-10)，192.0(C-11)，122.8(C-12)，178.5(C-13)，41.7(C-14)，25.8(C-15)，20.2(C-16)，46.1(C-17)，44.0(C-18)，43.5(C-19)，33.1(C-20)，31.6(C-21)，34.0(C-22)，29.9(C-23)，21.4(C-24)，23.0(C-25)，24.3(C-26)，26.3(C-27)，182.1(C-28)，33.1(C-29)，23.8(C-30).

Preparation embodiment 5LQC-X5's is synthetic

Take by weighing the about 500mg of LQC-X3, the 50ml acetone solution slowly drips the chromic acid solution (1.6mmol) of 4ml preparation under ice-water bath in the 100ml reaction flask, drip off in the 5min.Reaction is not to there being raw material, and reaction finishes.Reaction solution is poured in the mixture of ice and water of 600ml, stirred, placement is spent the night, suction filtration.Filter cake is used the ethanol periodic crystallisation, promptly gets LQC-X5.Reaction yield is 95%.

The LQC-X5 spectrum data of being correlated with:

¹H-NMR (500MHZ, CDCl ₃): 0.86,0.96,1.11,1.16,1.20,1.21,1.26 (3H, each, s, 7 * CH ₃), 3.20 (1H, d, J=2.5HZ, H-11), 5.29 (1H, d, J=2.5HZ, H-12), 1.000～2.500 (24H, methylene radical in the three obedient mother nucleus structures and methyne hydrogen signals);

¹³C-NMR(500MHZ，CDCl ₃)：34.0(C-1)，33.8(C-2)，215.4(C-3)，47.1(C-4)，48.9(C-5)，19.1(C-6)，30.9(C-7)，43.0(C-8)，78.4(C-9)，34.0(C-10)，50.0(C-11)，121.5(C-12)，144.2(C-13)，38.1(C-14)，28.8(C-15)，27.1(C-16)，49.2(C-17)，41.6(C-18)，46.4(C-19)，31.0(C-20)，40.7(C-21)，29.7(C-22)，21.8(C-23)，20.8(C-24)，17.3(C-25)，14.8(C-26)，20.7(C-27)，180.3(C-28)，27.7(C-29)，24.7(C-30).

Preparation embodiment 6LQC-X6's is synthetic

Take by weighing the about 0.62g of LQC-X1 (about 1.5mmol), the 50ml acetone solution slowly drips the chromic acid solution (1.6mmol) of 4ml preparation under ice-water bath in the 100ml reaction flask, drip off in the 5min.Reaction is not to there being raw material, and reaction finishes.Reaction solution is poured in the mixture of ice and water of 600ml, stirred suction filtration.Filter cake is mixed appearance, crosses silicagel column.Sherwood oil: ETHYLE ACETATE=100: 1 wash-outs promptly gets 0.46g LQC-X6.Reaction yield 67.3%, m.p.154.2-155.1 ℃.

The LQC-X6 spectrum data of being correlated with:

¹H-NMR(500MHZ，CDCl ₃)：0.93，0.97，1.03，1.06，1.08，1.13，1.26(3H，each，s，7×CH ₃)5.61(d，1H，J＝6.0HZ，H-12)，5.67(d，1H，J＝5.5HZ，H-11).

¹³C-NMR(500MHZ，CDCl ₃)：38.3(C-1)，37.7(C-2)，217.1(C-3)，47.3(C-4)，51.8(C-5)，19.5(C-6)，33.7(C-7)，40.7(C-8)，152.7(C-9)，42.6(C-10)，120.7(C-11)，117.4(C-12)，145.4(C-13)，45.9(C-14)，27.0(C-15)，23.6(C-16)，45.8(C-17)，39.5(C-18)，26.0(C-19)，30.7(C-20)，34.5(C-21)，32.1(C-22)，31.3(C-23)，21.3(C-24)，20.0(C-25)，20.1(C-26)，26.0(C-27)，182.7(C-28)，32.9(C-29)，23.6(C-30).

Preparation embodiment 7LQC-X7's is synthetic

Take by weighing compound 1 about 0.62g (about 1.5mmol), the 50ml acetone solution slowly drips the chromic acid solution (1.6mmol) of 4ml preparation under ice-water bath in the 100ml reaction flask, drip off in the 5min.Reaction is not to there being raw material, and reaction finishes.Reaction solution is poured in the mixture of ice and water of 600ml, stirred suction filtration.Filter cake is mixed appearance, crosses silicagel column.Sherwood oil: ETHYLE ACETATE=50: 1 wash-outs promptly gets 0.50g LQC-X7.Reaction yield 73.15%, m.p.211.8-212.7 ℃.

The LQC-X7 spectrum data of being correlated with:

¹H-NMR (500MHZ, CDCl ₃): 0.82,0.93,0.96,1.01,1.05,1.08,1.19 (s, 3H, each, 7 * CH ₃), 3.22 (m, 1H, 3, β-CH), 5.24 (brs, 1H, 12-CH), 1.000～2.500 (24H, methylene radical in the three obedient mother nucleus structures and methyne hydrogen signals);

¹³C-NMR(500MHZ，CDCl ₃)：38.5(C-1)，27.3(C-2)，219.0(C-3)，38.8(C-4)，54.2(C-5)，18.3(C-6)，33.3(C-7)，38.8(C-8)，47.6(C-9)，37.6(C-10)，24.7(C-11)，122.5(C-12)，144.6(C-13)，41.5(C-14)，27.7(C-15)，23.2(C-16)，45.9(C-17)，41.8(C-18)，45.7(C-19)，30.6(C-20)，32.9(C-21)，32.3(C-22)，28.1(C-23)，15.6(C-24)，15.3(C-25)，16.8(C-26)，25.9(C-27)，177.3(C-28)，32.5(C-29)，24.4(C-30).

Preparation embodiment 8LQC-X8's is synthetic

The Ligustrazine 10g that will dewater is dissolved in 60mlCCl ₄In; Again according to mol ratio Ligustrazine: NBS=1: 0.7 drops into NBS 9.17g (Lucidol that can add trace is a radical initiator), under the incandescent light irradiation, and back flow reaction 10～12h; Cooling; Concentrate, in 60～70 ℃ of water-baths, take excessive Ligustrazine away under the decompression situation, leave standstill in resistates to the refrigerator.Obtain incarnadine half oily matter 7.75g, productive rate 70%.

2-bromomethyl-3,5,6-trimethylpyrazine 3.26mmol, Oleanolic Acid 3.26mmol place the 150ml three-necked bottle, add the 80ml tetrahydrofuran solvent; The salt of wormwood that adds 9mmol, reflux 2.5h, TLC monitoring reaction raw material disappears stopped reaction basically; Remove by filter salt of wormwood, filtrating is concentrated into a small amount of THF, adds 4g silica gel evaporated under reduced pressure and mixes appearance; Eluent is a sherwood oil: ETHYLE ACETATE=3: 2 wash-outs obtains LQC-X8, white powder thing 1.26g; Productive rate 65.6%, 133.8～134.4 ℃ of fusing points

LQC-X8 hydrogen spectrum and carbon spectrum data are following:

¹H-NMR (500MHZ, CDCl ₃): 0.552,0.799,0.895,0.907,0.927,1.002,1.127 (s, 3H, each, 7 * CH ₃), 3.225 (m, 1H, 3, β-CH), 5.257 (brs, 1H, 12-CH), 5.257 (q, 2H, O-CH ₂), 2.575 (s, 3H, 6-CH ₃), 2.536 (s, 3H, 5-CH ₃), 2.516 (s, 3H, 3-CH ₃), 1.000～2.500 (24H, methylene radical in the three obedient mother nucleus structures and methyne hydrogen signals);

¹³C-NMR (500MHZ, CDCl ₃): 38.4 (C-1), 27.2 (C-2), 79.0 (C-3), 38.8 (C-4), 55.2 (C-5), 18.3 (C-6), 33.1 (C-7); 39.2 (C-8), 47.6 (C-9), 37.0 (C-10), 23.7 (C-11), 122.5 (C-12), 143.6 (C-13); 41.7 (C-14), 27.6 (C-15), 23.1 (C-16), 46.9 (C-17), 41.3 (C-18), 45.9 (C-19); 30.7 (C-20), 33.9 (C-21), 32.7 (C-22), 28.1 (C-23), 15.6 (C-24), 15.3 (C-25); 16.8 (C-26), 25.9 (C-27), 177.2 (C-28), 32.4 (C-29), 23.4 (C-30), 64.9 (O-CH ₂-); δ C:150.9 (C-2) on the pyrazine ring, 145.5 (C-3), 148.9 (C-5), 149.1 (C-6), 21.6 (6-CH ₃), 21.4 (5-CH ₃), 20.5 (3-CH ₃);

Preparation embodiment 9LQC-X9's is synthetic

2-bromomethyl-3,5,6-trimethylpyrazine 0.15mol, 0.15mol LQC-X1 place the 500ml three-necked bottle, after the thing dissolving to be mixed of adding 300ml THF; The salt of wormwood that adds 50g, reflux 2.5h, TLC monitoring reaction raw material disappears stopped reaction basically; Add 5 times of amount ETHYLE ACETATE in the reaction solution,, obtain the organic layer evaporate to dryness with saturated NaCl water liquid washing 3 times; Proper amount of acetone is redissolved, and silicagel column separates, and eluent is a sherwood oil: ETHYLE ACETATE=5: 1 or sherwood oil: acetone=10: 1; Obtain white powder thing LQC-X9, productive rate 70%, 220.8～221.5 ℃ of fusing points.

LQC-X9 hydrogen spectrum and carbon spectrum data are following:

¹H-NMR (500MHZ, CDCl ₃): 0.799,0.837,0.927,1.007,1.032,1.089,1.185 (s, 3H, each, 7 * CH ₃), 3.032 (m, 1H, H-3), 5.573 (d, 1H, J=5.5HZ, H-12), 5.585 (d, 1H, J=5.5HZ, H-12), 5.199 (q, 2H, O-CH ₂), 2.579 (s, 3H, 6-CH ₃), 2.538 (s, 3H, 5-CH ₃), 2.512 (s, 3H, 3-CH ₃), 1.000～2.500 (24H, methylene radical in the three obedient mother nucleus structures and methyne hydrogen signals);

¹³C-NMR (500MHZ, CDCl ₃): 38.8 (C-1), 37 (C-2), 78.5 (C-3), 38.7 (C-4), 51.0 (C-5), 18.2 (C-6), 33.8 (C-7); 39.5 (C-8), 154.6 (C-9), 42.3 (C-10), 120.5 (C-11), 115.7 (C-12), 144.6 (C-13); 45.8 (C-14), 27.8 (C-15), 23.7 (C-16), 45.9 (C-17), 39.5 (C-18), 25.2 (C-19); 30.7 (C-20), 33.0 (C-21), 32.7 (C-22), 28.1 (C-23), 15.3 (C-24), 20.1 (C-25); 20.2 (C-26), 26.9 (C-27), 177.3 (C-28), 32.8 (C-29), 23.5 (C-30), 64.8 (O-CH ₂-); δ C:150.9 (C-2) on the pyrazine ring, 145.6 (C-3), 148.8 (C-5), 150.9 (C-6), 21.7 (6-CH ₃), 21.5 (5-CH ₃), 20.3 (3-CH ₃);

Preparation embodiment 10LQC-X10's is synthetic

2-bromomethyl-3,5,6-trimethylpyrazine 0.15mol, 0.15mol LQC-X6 place the 500ml three-necked bottle, after the thing dissolving to be mixed of adding 300ml THF; The salt of wormwood that adds 50g, reflux 2.5h, TLC monitoring reaction raw material disappears stopped reaction basically; Add 5 times of amount ETHYLE ACETATE in the reaction solution,, obtain the organic layer evaporate to dryness with saturated NaCl water liquid washing 3 times; Proper amount of acetone is redissolved, and silicagel column separates, and eluent is a sherwood oil: ETHYLE ACETATE=5: 1 or sherwood oil: acetone=10: 1; Obtain white powder thing LQC-X10, productive rate 65%, 119.2～120.8 ℃ of fusing points.

LQC-X10 hydrogen spectrum and carbon spectrum data are following:

¹H-NMR (500MHZ, CDCl ₃): 0.821,0.903,0.946,1.033,1.056,1.105,1.235 (s, 3H, each, 7 * CH ₃), 5.578 (d, 1H, J=6.0HZ, H-12), 5.589 (d, 1H, J=5.5HZ, H-12), 5.197 (q, 2H, O-CH ₂), 2.582 (s, 3H, 6-CH ₃), 2.560 (s, 3H, 5-CH ₃), 2.512 (s, 3H, 3-CH ₃), 1.000～2.500 (24H, methylene radical in the three obedient mother nucleus structures and methyne hydrogen signals);

¹³C-NMR (500MHZ, CDCl ₃): 38.3 (C-1), 37.7 (C-2), 217.6 (C-3), 47.3 (C-4), 51.8 (C-5), 19.5 (C-6), 33.8 (C-7); 40.7 (C-8), 152.8 (C-9), 42.5 (C-10), 120.3 (C-11), 117.5 (C-12), 145.2 (C-13); 45.9 (C-14), 27.6 (C-15), 23.6 (C-16), 45.9 (C-17), 39.2 (C-18), 25.7 (C-19); 30.7 (C-20), 33.9 (C-21), 32.6 (C-22), 31.4 (C-23), 21.3 (C-24), 20.4 (C-25); 20.8 (C-26), 26.4 (C-27), 177.0 (C-28), 32.9 (C-29), 23.7 (C-30), 64.8 (O-CH ₂-); δ C:150.8 (C-2) on the pyrazine ring, 145.4 (C-3), 148.7 (C-5), 148.9 (C-6), 21.5 (6-CH ₃), 21.4 (5-CH ₃), 20.4 (3-CH ₃);

Effect embodiment 1LQC-X is to the influence of HepG2.2.15 cell hepatitis b virus marker

1. material

1.1 cell

The HepG2.2.15 cell strain is gone down to posterity to protect by 302 hospital infectious disease institutes of PLA and plants.

1.2 experiment medicine

LQC-X series compound (self-control), liquid chromatography (HPLC) analysis carry out purity and identify that purity >=98% meets requirement of experiment.Powder-tight is stored in 4 ℃ well.Use anhydrous alcohol solution subsequent use as the storage liquid of 5ml/mg.

2. method

2.1 cell cultures:

With the HepG2.2.15 cell recovery, the cultivation of going down to posterity treats that the cell growth is stable, following step experiment.Use trypsin digestion cell, process cell suspension.With the cell plate counting, calculate cell concentration, add complete nutrient solution, dispose certain cell concn.

2.2 cell inhibitory effect experiment

The cell of taking the logarithm vegetative period is with 1 * 10 ⁵/ ml density is inoculated in 96 orifice plates, every hole 100 μ l.In 37 ℃, 5%CO ₂Cultivate 24h in the incubator.Nutrient solution is abandoned in suction, adds the LQC-X solution (to contain the different final concentration of 10% calf serum DMEM nutrient solution preparation) of 200 μ l different concns, and each concentration is established 4 parallel holes.After cultivating 144h, the careful suction abandoned culture supernatant in the hole, and every hole adds 5% calf serum DMEM nutrient solution, 100 μ l, and every hole adds MTS 20 μ l again, and mixing is in 37 ℃ of 5%CO ₂Incubator is hatched 3h, and with enzyme scalar quantity tester, the 490nm place surveys absorbancy.Experiment repetition 3 times.Calculate inhibiting rate.

Inhibitory rate of cell growth (%)=[(the average OD value of the control group-average OD value of medication group)/average OD value of control group] * 100%

2.3LQC-X to antigenic inhibition experiment in the HepG2.2.15 emiocytosis supernatant

By experimental design trial drug is made into four concentration below the non-toxic concn, adds 96 orifice plates respectively, the negative control group in pure culture liquid hole of not dosing is established in multiple 4 holes, hole of every concentration simultaneously.With the positive contrast of lamivudine.If four concentration, multiple 4 holes, hole of every concentration.Medication was received supernatant after 4 days, and it is to be measured to put-20 ℃ of preservations.

The cell conditioned medium liquid of-20 ℃ of preservations is put 37 ℃ of water-baths melt, detect, calculate inhibiting rate respectively with formula through the ELISA method.

Inhibiting rate=[control wells OD value-experimental port OD value]/control wells OD value * 100%

The ELISA experimentation:

(1) every hole adds testing compound 100 μ l, establishes the positive and negative control wells, and establishes 1 hole, blank hole.Putting 37 ℃ hatched 1 hour.

(2) by hand wash plate: discard the liquid hole in, the PBS washings is filled with each hole, leaves standstill 5 seconds, dries, repeats 3 times after bat dried.

(3) except that the blank hole, every hole adds enzyme conjugates 100 μ l, and fully the mixing shrouding is put 37 ℃ and hatched 30 minutes.

(4) by hand wash plate: discard the liquid hole in, the PBS washings is filled with each hole, leaves standstill 5 seconds, dries, repeats 4 times after bat dried.

(5) every hole adds developer A liquid, each one of B liquid, and abundant mixing, shrouding is put 37 ℃ and was hatched 15 minutes.

(5) every hole adds mixing of stop buffer.

(6) enzyme mark 450nm detects the OD value in the place, selects the blank well zeroing for use, reads the value in each hole then.

2.4LQC-X to antigenic inhibition experiment in the HepG2.2.15 emiocytosis supernatant

Collect the nutrient solution of 4d behind several kinds of compound treatment HepG2.2.15 cells, 8d, press operation instructions in the hepatitis B virus nucleic acid detection by quantitative test kit, detect HBV-DNA content in the supernatant.

3. result

3.1 cell inhibitory effect experimental result

Have 8 HepG2.2.15 cells to vitro culture to have the inhibited proliferation that is dose-dependently in 10 compounds of LQC-X series, the result is like table 1-1.Wherein LQC-X6, LQC-X7, LQC-X8, LQC-X9 are particularly evident; When drug level is 12.5 μ g/ml; The inhibiting rate of pair cell surpasses 50% basically, and along with the increase of drug level, inhibiting rate rises gradually; When drug level was 50 μ g/ml, the inhibiting rate of pair cell reached 96.15%, 95.83%, 94.85% and 94.28% respectively.Experimental result shows that the restraining effect of LQC-X series compound pair cell has selectivity preferably, and its effect and drug level and action time are proportionate.Compound L QC-X6, LQC-X7, LQC-X8, LQC-X9 infer that tentatively it has certain curative effect at anti-tumor aspect because significant inhibition cel l proliferation is arranged.

Table 1-1LQC-X is to the inhibited proliferation of HepG2.2.15

3.2LQC-X to antigenic inhibition result in the HepG2.2.15 emiocytosis supernatant

Can know that by table 1-2,1-3 the LQC-X series compound all has certain restraining effect to the antigen of hepatitis B virus of HepG2.2.15 emiocytosis.LQC-X6 has significant inhibitory effect to surface antigen (HBsAg) below non-toxic concn, be excellent than other compounds and positive drug, and certain dose-dependently is arranged.LQC-X6, LQC-X7, LQC-X8 and LQC-X9 have significant inhibitory effect to e antigen (HBeAg) below non-toxic concn, effect is excellent than positive drug.

Table 1-2LQC-X is to the restraining effect of surface antigen in the HepG2.2.15 emiocytosis supernatant

Table 1-3LQC-X is to the antigenic restraining effect of e in the HepG2.2.15 emiocytosis supernatant

3.3LQC-X inhibition result to HepG2.2.15 cell HBV-DNA

LQC-X7 all has certain restraining effect to the propagation of HBV-DNA when 4d and 8d, LQC-X6 had the proliferation function of significant inhibition HBV-DNA in the time of 8 days, and the result is like table 1-4.

Table 1-4LQC-X is to the inhibition result of HepG2.2.15 cell HBV-DNA

4. conclusion

The LQC-X series compound, pair cell excretory hepatitis B antigen all has certain restraining effect.Wherein, LQC-X6 can significantly suppress excretory HBsAg and HBeAg in the HepG2.2.15 emiocytosis supernatant, and is in the time of 8 days, comparatively obvious to the inhibition of hepatitis B viruses (HBV)-DNA in the cell administration.Therefore, LQC-X6 has comparatively remarkable vitro anti-hepatitis B virus activities.

The research of anti-dhbv dna in the effect embodiment 2LQC-X6 body

1. material

1.1 animal

30 of 1 age in days Beijing ducks, male, the about 60g of body weight.

1.2 experiment medicine

LQC-X6 (self-control), lamivudine is provided by biotechnology.Powder-tight is stored in 4 ℃ well.

1.3 virus

DHB DNA (DHBV-DNA) strong positive serum is measured its DHBV titre, according to comparing with quantitative clone DHBV-DNA, calculates every milliliter of virion number that serum is contained, one 70 ℃ of preservations; Or DHBV plasmid.

2. method

2.1 duplicate the duck hepatitis B virus infection model

Get 30 of 1 age in days Beijing ducks, be divided into 5 groups at random: model control group, positive controls, the high, medium and low dose groups of compound.Every group 6.In 1～3d, every through leg shin intravenous injection 0.2ml DHBV-DNA strong positive duck serum, and the virus inoculation amount is 7.5 * 10 ⁷～5 * 10 ⁹

2.2 pharmacological agent

7d gets blood from duck leg shin vein after infection, separation of serum, and for treating preceding sample (T0), one 70 ℃ of preservations are to be checked.DHBV carries out the pharmacological agent test after infecting duckling 7d, and the high, medium and low dose groups of compound gives 100,50 and 25mg/kg every day respectively, and positive controls gives lamivudine 50mg/kg every day, and model control group gives saline water.By body weight administration 2ml/kg, gastric infusion, every day 2 times, 10d in medication the 5th day (T5), after the 10th day (T10) and the drug withdrawal the 3rd day (P3), gets blood from duck leg shin vein continuously, separation of serum, one 70 ℃ of preservations are to be checked.

2.3 the detection of duck serum DHBV-DNA

Adopt DHBV-DNA Dot Blot method to measure.Get above-mentioned duck serum, every batch with the time point film, measures DHBV-DNA level in the duck serum, observes its dynamic change.Press nick translation test kit specification sheets method, use ³²P mark DHBV-DNA probe is put 40 μ l serum on nitrocellulose membrane, hybridization then, and radioautograph is measured OD value (wavelength is 490nm) on enzyme mark detector.Calculate serum DHBV-DNA density, with hybridization spot OD value as sample DHBV-DNA level value.

2.4 drug effect is calculated

that calculate every group of different time points serum DHBV-DNA level organizes the medication front and back and relatively adopts paired t-test; Calculate the DHBV-DNA inhibiting rate, respectively organize the dynamic change of duck serum DHBV-DNA inhibiting rate.Administration group and virus control group relatively adopt t check in groups.

OD value * 100% before DHBV-DNA inhibiting rate=(OD value after preceding OD value one administration of administration)/administration

3. experimental result

The middle and high dose groups of LQC-X6 compares with infection provirus titre respectively, and certain difference is all arranged, and with the increase of treatment fate, curative effect increases, and is dose-dependently.After the drug withdrawal three days, the LQC-X6 high dose group is better than the effect of lamivudine to the restraining effect of virus, explains that LQC-X6 on to the rebound phenomenon after the anti-hbv drug treatment, has meliority.The result sees table 2-2.Show that this compound has certain restraining effect to dhbv dna.

Table 2-1 LQC-X6 treatment group and virus infection control group duck serum

DHBV-DNA OD value relatively

Statistical treatment: t1, p1: (T5, T10, P3) duck serum DHBV-DNAOD value compares (paired t-test) with preceding (T0) OD value of infection to administration group different time.*p1＜0.05，**p1＜0.01。

Table 2-2 medication therapy groups and virus infection control group duck serum

The DHBV-DNA level is faced upward the comparison of system rate.

Statistical treatment: t2, p2: (T5, T10, P3) duck serum DHBV-DNA level suppresses % relatively (t checks in groups) with infection preceding (T0) inhibition % and virus control group relatively to administration group different time.*p＜0.05，**p2＜0.01。

4. conclusion

LQC-X6 has the effect of remarkable inhibition dhbv dna in the duckling body, and is a certain amount of effect relationship.

Effect embodiment 3LQC-X6 is to the provide protection of tetracol phenixin induced mice acute liver damage

1. material

1.1 laboratory animal

Healthy Kunming mouse, body weight 18～22g, male and female half and half, dimension tonneau China Experimental Animal Center provides.

1.2 experiment medicine

LQC-X6 (synthetic voluntarily) by this laboratory, lot number 20100315, liquid chromatography (HPLC) analysis is carried out purity and is identified that purity >=98% meets requirement of experiment, prepares with saline water during experiment; Tetracol phenixin, Beijing's chemical reagent factory, lot number 20021113.

2. method

2.1 divide into groups and administration

Mouse is divided into 3 groups at random, 10 every group: and sample sets (LQC-X6,40mg/kg), blank group and model group (equal-volume saline water), 1 time/d of gastric infusion, successive administration 14d.During this time, observe the situation such as general activity, fur, ight soil of mouse every day.

2.2 duplicate the acute liver damage model

7th, behind 14 days administration 1h, all the other respectively organize equal abdominal injection 0.2%CCl except that the blank group ₄Olive oil solution 10ml/kg, fasting 24h weighs in, and plucks eyeball and gets blood, 3000r/min is centrifugal, gets supernatant, and take out liver fast, spleen weighs.

2.3 biochemical indicator is measured

The activity of Serum ALT, AST is detected by the 3rd affiliated hospital of Beijing University of Chinese Medicine.

2.4 pathological examination

Get the part hepatic tissue, put in 10% formaldehyde solution and fix, specimens paraffin embedding slices, HE dyeing, mirror is observed down.

2.5 statistical method

Adopt SAS 8.0 softwares to carry out the t check.

3. experimental result

3.1 biochemical indicator

Model group and blank group compare, Serum ALT, active obviously raise (P＜0.01) of AST.Compare with model group, LQC-X6 group serum AL T, AST level all significantly reduce (P＜0.01).The result sees table 1.

Table 3-1 respectively organizes mice serum inspection index

Annotate: compare with blank control group ^{△ △}P＜0.01; Compare * * P＜0.01 with model group.

3.2 liver morphological change

Finding of naked eye: blank group liver presents sorrel, the soft and high resilience of quality; The liver volume of model group obviously increases, and matter is crisp, and the surface is little yellow, and with oily matter; LQC-X6 group liver size and the equal boundary of color are between model group and blank group.

The light microscopic finding: blank group Mouse Liver leaflet structure is normal, clear, the cell marshalling, and size is even, and nucleus is positioned at cell central authorities, justifies and clear border; The obvious oedema of model group mouse liver cell, balloon appearance become, liver cell arrangement disorder, crowded, and visible hepatic cords dissociates, spotty necrosis in the liver lobule, there are a large amount of cell infiltration the portal area; And the most of liver cell structural integrity of LQC-X6 administration group, marshalling, liver cell oedema, balloon appearance become and cell infiltration all obviously alleviates.

4. conclusion

4.1LQC-X6 can significantly reduce the biochemical indicator of liver injury mouse due to the tetracol phenixin.

4.2LQC-X6 can significantly slow down the hepar damnification degree of liver injury mouse due to the tetracol phenixin, retardance hepar damnification process.

Effect embodiment 4LQC-X6 is to the provide protection of rat chronic hepatic fibrosis due to the tetracol phenixin

1. experiment material

1.1 laboratory animal

SPF level SD rat, body weight 180～220g, male and female half and half, dimension tonneau China Experimental Animal Center provides.

1.2 experiment medicine

Receive reagent thing: LQC-X6, Beijing University of Chinese Medicine Chemistry for Chinese Traditional Medicine laboratory is synthetic, lot number 20100315; Positive control drug: Biphenylylmethylcarbinol (BPD), a Guangzhou group of stars (medicine company) limited-liability company produces.

1.3 reagent

Tetracol phenixin (CCl ₄), Beijing's chemical reagent factory (analytical pure); Sweet oil.

1.4 instrument

BP211D ten thousand/gram electronic balance, German Sai Duolisi; Micro sample adding appliance, Germany; LG one 16 one W type whizzers, Beijing Medical Centrifugal Machine Factory; High speed low temperature centrifugal machine.

2. experimental technique

2.1 administration is divided into groups

Select the SD rat for use, male and female half and half, body weight (200 ± 30) g is divided into 6 groups at random with animal, i.e. blank group, CCl ₄Model group, the positive group of Biphenylylmethylcarbinol (BPD), LQC-X6 high and low dose treatment group, not modeling of LQC-X6 high dosage control group.

2.2 modeling and administration

Except that blank control group and not modeling of LQC-X6 high dosage control group, equal modeling is organized in model group and treatment.With CCl ₄Be made into 40%CCl with sweet oil in 2: 3 ratios ₄Oil solution is used for modeling.Except blank control group and medicine control group, all the other the 4 groups of equal abdominal injection 2ml/kg of rat 40%CCl ₄Oil solution, twice weekly (5ml/kg first), blank control group and high dosage control group are with the sweet oil of method injection 2ml/kg, totally 9 weeks.Trial drug group dosage is according to the mensuration result of duck hepatitis B drug effect; Convert by body surface area in conjunction with its clinical application amount, the positive drug group is pressed the clinical administration effective dose, in conjunction with dosage conversion Of Mice and Men; The administration group is all by body weight 10ml/kg dosage, and every day, gastric infusion was 1 time.Weigh every other day; Press ABW adjustment administration and modeling dosage; Blank control group and LQC-X6 high dosage control group are irritated the saline water that stomach gives Isodose, and positive group is irritated stomach and given BPD (10.5mg/kg), test medication LQC-X6 high (28mg/kg), low (14mg/kg) dosage.

2.3 collection of specimens

Each treated animal is total to 70d when the 9th weekend, water 12h is can't help in fasting, and frog board is rat fixedly, and blood is got in the femoral artery bloodletting, separation of serum.Put to death the blood sampling back, dissects, and gets the hepatomegaly leaf, and 4% Paraformaldehyde 96 is fixed, and by ordinary method preparation section, under light microscopic, carries out pathological examination.

2.4 detect index and method

1. serum biochemistry is learned inspection: send the 3rd affiliated hospital of Beijing University of Chinese Medicine to detect Serum ALT, AST activity.2. liver organization biochemical analysis: get fresh left lobe of liver, fix, make the pathology paraffin section, do HE dyeing, observe hepatic tissue structure and proliferation of fibrous tissue situation in microscopically with 4% paraformaldehyde solution.

2.5 statistical method

Each is organized data and representes that with

employing SAS 8.0 softwares carry out the variance between laboratories analysis.

3. experimental result

3.1 biochemical indicator

Rat femoral is got blood, and centrifuging and taking serum detects ALT, AST.The result sees table 4-1.4-1 is visible by table, abdominal injection CCl ₄9 week back model group rats'liver function each item indexs (ALT, AST) obviously raise than the blank group, and positive group is more remarkable to the restraining effect of ALT, AST, and LQC-X6 high and low dose group all has certain restraining effect to ALT, AST.

Table 4-1 medicine is to the influence of chronic hepatic injury rats'liver function

Compare with blank control group: ^△P＜0.01, ^{△ △}P＜0.05; Compare with model group: * P＜0.01, * * P＜0.05.

3.2 the weight of animals

4-2,4-3 are visible by table; After experiment finished, the model group body weight obviously descended than blank control group, and LQC-X6 treatment group is more obvious than weight loss with blank control group; But not modeling of LQC-X6 control group also has remarkable decline than the blank control group body weight, infers that LQC-X6 possibly have the effect that loses weight to animal.Because female, tom body weight differs greatly, so do not add up together.

Table 4-2 medicine is to the influence of chronic hepatic injury rat (male) body weight

Table 4-3 medicine is to the influence of chronic hepatic injury rat (female) body weight

3.3 organ coefficient

4-4 is visible by table, and after experiment finished, model group rat liver organ coefficient obviously increased (P＜0.01) than blank control group, and LQC-X6 treatment group is low, high dosage all has reduction than model group, and wherein the LQC-X6 high dose group has obvious reduction, and effect is superior to the positive drug group.

Table 4-4 medicine is to the influence of thing chronic hepatic injury rats'liver spleen coefficient

Compare with blank control group: ^△P＜0.01, ^{△ △}P＜0.05; Compare with model group: * P＜0.01, * * P＜0.05

3.4 hepatic pathology histological examination result

Visual inspection: during off-test, liver is checked, found except that blank control group and not modeling of LQC-X6 control group that all the other are respectively organized, and all visible volume increase, the color in various degree of liver shoals, sclerosis and edge rust; Histological examination is found, also visible liver injury in various degree comprises the acute injury and the chronic injury of hepatic tissue.Acute injury comprises the change of balloon appearance, steatosis and the necrosis of cell, and wherein steatosis is the slight steatosis of small amounts of cells in each group, indifference between group, and balloon appearance becomes and the group difference of degree of necrosis is bigger; Chronic fibrosis comprises that partial reticulin fiber support subsides, the reticulin fiber hyperplasia, and be fused into collegen filament, and the outgrowth fibrous tissue of the lighter forms little interval, and weight person's liver subregion is not obvious, and outgrowth fibrous septum interconnects, and forms pseudolobuli.

Microscopy is found blank group and not modeling of LQC-X6 control group, and rats'liver leaflet, portal area structure are normal; Model group liver cell severe edema fat becomes, and hole parietal cell hyperplasia is obvious, and the fibrous septum is wide, and 90% above liver specimen has the pseudolobuli of filling the air to form, and a small amount of chronic inflammation cellular infiltration is arranged in portal area and the fibrous septum, with the blank control group comparing difference significance is arranged; LQC-X6 high and low dose treatment group fiber asks at a distance from thin pseudolobuli and forms minimizing that lesion degree obviously alleviates than model group, and certain dose-dependently is arranged.

4. conclusion

4.1LQC-X6 can significantly reduce the biochemical indicator of hepatic fibrosis rats due to the tetracol phenixin.

4.2LQC-X6 finish the back in experiment rat is had certain effect of losing weight, concrete reason needs further to inquire into.

4.3LQC-X6 the treatment group can suppress the rising of liver injury Rats Organs and Tissues coefficient, and the effect of certain protection internal organs is arranged.

4.4LQC-X6 can significantly slow down the hepar damnification degree of hepatic fibrosis rats due to the tetracol phenixin, retardance hepar damnification process.

Toxicity embodiment 1

Experimental project: the LQC-X6 mouse is through abdominal injection LD ₅₀(Bliss method)

One, experiment material:

KM small white mouse [male and female half and half, 18-22g] is available from dimension tonneau China Experimental Animal Center.

LQC-X6, white powder (self-control), with the salad oil dilution, existing with join at present.

Two, experimental technique:

Adopt KM kind mouse, weight range 18-22g provides (SPF level) by Beijing Vital River Experimental Animals Technology Co., Ltd..Test dose is the maximum dose level group with 1000mg/kg, with the mouse random packet, and 6 every group, male and female half and half, abdominal injection 0.2ml/10g.Observed various reactions of record animal and the dead number of elements of each group 7 days.According to the mortality ratio of each treated animal, calculate LD with the Bliss method ₅₀And fiducial limit.

Three, experimental result:

After administration, in 12 hours, do not see death, respectively organize the dead mouse situation in 7 days and see the following form 1:

The table 1-1 with the LQC-X6 mouse through abdominal injection LD50 (Bliss method)

Regression equation y (Probit)=-23.294+9.7738Log (D)

Medium lethal dose(LD&-{50}) LD50=785.05mg/kg

Fiducial limit=650.58--929.07mg/kg of LD50 (Feiller correction) 95%

LD5＝532.84mg/kg

LD95＝1156.6mg/kg

Four, conclusion:

The LQC-X6 mouse is 785.05mg/kg through abdominal injection LD50 (Bliss method), and 95% credibility interval is 650.58--929.07mg/kg.

Five. brief summary: the LQC-X6 security is higher.

Toxicity embodiment 2

One, experimental project: the oral acute toxicity test of LQC-X6 mouse

Two, experiment material:

ICR small white mouse [male and female half and half, 18-22g, animal license licensed licenser licence numbering: SCXK (capital) 2006-0009]

LQC-X6, white powder (self-control) is dissolved in this medicine of 5000mg in 100ml 0.5% Xylo-Mucine, and ultrasonic suspendible is existing with join at present.

Three, experimental technique:

The qualified animal of quarantining is weighed before the administration, carries out random packet according to body weight, adopts mouse stomach device gastric infusion.Before the mouse administration, fasting can't help water and is spent the night (continuous 14 hours), begins single maximal dose administration (2000mg/kg) in administration 9:00 in the morning on the same day, observes feeding after 1 hour continuously.

Four, experimental result:

After administration, in 12 hours, do not see death, respectively organize the dead mouse situation in 7 days and see the following form:

The oral acute toxicity test overview of table 7LQC-X6 mouse is summary sheet as a result

Annotate: √ representes standard state

Five, brief summary:

In the oral acute toxicity test of this LQC-X6 mouse, mouse gives single the maximum stomach dosage 2000mg/kg that irritates, and observes continuously in 7 days, toxic reaction do not occur, shows that the security of this medicine is very high.

Toxicity embodiment 3

One, experimental project: the therapeutic index of LQC-X6 hepatoprotective effect

Two, experiment material: (the fruit embodiment 3 that takes effect, toxicity embodiment 2)

Three, experimental technique: (the fruit embodiment 3 that takes effect, toxicity embodiment 2)

Four, experimental result: (the fruit embodiment 3 that takes effect, toxicity embodiment 2)

Can know by effect embodiment 3, when LQC-X6 dosage is 40mg/kg, can significantly reduce the biochemical indicator of liver injury mouse due to the tetracol phenixin, can significantly slow down the hepar damnification degree of liver injury mouse due to the tetracol phenixin, retardance hepar damnification process; Can know that in conjunction with toxicity embodiment 2 the maximum filling of LQC-X6 mouse single stomach dosage is 2000mg/kg mg/kg, its therapeutic index TI should be not less than 50.

Five, brief summary:

TI is greater than 50 for the LQC-X6 therapeutic index, explains that the LQC-X6 security is higher, and hepatoprotective effect is obvious.

FORMULATION EXAMPLE 1

Get LQC-X 10g, add suitably auxiliary material of injection (comprising lyophilized injectable powder and aseptic subpackaged dry powder injection), become hepatitis B resisting medicated injection by injection (comprising lyophilized injectable powder and aseptic subpackaged dry powder injection) prepared.

FORMULATION EXAMPLE 2

Get LQC-X 10g, add suitably auxiliary material of tablet (comprising slow-release tablet, matrix tablet, coating tablet, dispersible tablet etc.), become hepatitis B resisting medicated tablet by tablet (comprising slow-release tablet, matrix tablet, coating tablet, dispersible tablet etc.) prepared.

FORMULATION EXAMPLE 3

Get LQC-X 10g, add the suitable auxiliary material of capsule, become hepatitis B resisting medicated capsule by the capsule prepared.

FORMULATION EXAMPLE 4

Get LQC-X 10g, add suitably auxiliary material of emulsion (comprising micro emulsion, nano-emulsion etc.), become hepatitis B resisting medicated emulsion by emulsion (comprising micro emulsion, nano-emulsion etc.) prepared.

FORMULATION EXAMPLE 5

Get LQC-X 10g, add the suitable auxiliary material of granule, become hepatitis B resisting medicated granule by the granule prepared.

FORMULATION EXAMPLE 6

Get LQC-X 10g, add the suitable auxiliary material of sustained-release and controlled release agent, become hepatitis B resisting medicated sustained-release and controlled release agent by sustained-release and controlled release agent prepared.

FORMULATION EXAMPLE 7

Get LQC-X 10g, add the suitable auxiliary material of oral liquid, become hepatitis B resisting medicated oral liquid by the oral liquid prepared.

FORMULATION EXAMPLE 8

Get LQC-X 10g, add the suitable auxiliary material of liposome formulation, become hepatitis B resisting medicated liposome formulation by the liposome prepared.

Claims

1. compound of Formula I

LQC-X general structure I

2. according to the preparation method of the said compound of claim 1, it is characterized in that the preparation of compound comprises the steps:

3. the application in the hepatitis B medicament is prevented and treated to the purposes of compound as claimed in claim 1 in preparation.

4. the purposes of compound as claimed in claim 2, the application in disease medicaments such as preparation prevention and treatment liver cirrhosis.